Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Zeina Al-Mansour; Hongli Li; James R. Cook; Louis S. Constine; Stephen Couban; Douglas A. Stewart; Thomas C. Shea; Pierluigi Porcu; Jane N. Winter; Brad S. Kahl; Sonali M. Smith; Deborah C. Marcellus; Kevin P. Barton; Glenn M. Mills; Michael LeBlanc; Lisa M. Rimsza; Stephen J. Forman; John P. Leonard; Richard I. Fisher; Jonathan W. Friedberg; Patrick J. Stiff

doi:10.1080/10428194.2018.1563691

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Zeina Al-Mansour, Hongli Li, James R. Cook, Louis S. Constine, Stephen Couban, Douglas A. Stewart, Thomas C. Shea, Pierluigi Porcu, Jane N. Winter, Brad S. Kahl, Sonali M. Smith, Deborah C. Marcellus, Kevin P. Barton, Glenn M. Mills, Michael LeBlanc, Lisa M. Rimsza, Stephen J. Forman, John P. Leonard, Richard I. Fisher, Jonathan W. FriedbergPatrick J. Stiff

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

11 Citas (Scopus)

Resumen

Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility (n = 1), choice (n = 2), or progression (n = 9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (p =.56), and 40% vs. 45% (p =.98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.

Idioma original	English
Páginas (desde-hasta)	1934-1941
Número de páginas	8
Publicación	Leukemia and Lymphoma
Volumen	60
N.º	8
DOI	https://doi.org/10.1080/10428194.2018.1563691
Estado	Published - jul. 3 2019
Publicado de forma externa	Sí

Nota bibliográfica

Funding Information:
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180888, CA180819, CA180820, CA180821, CA180863, CCSRI #021039; legacy grants CA46282, CA04919, CA11083, CA58658, CA46368, CA13612; and in part by Bristol-Myers Squibb. The content is solely the responsibility of the authors and does not necessarily represent the official views of either the National Institutes of Health or Bristol-Myers Squibb.

Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

ASJC Scopus Subject Areas

Hematology
Oncology
Cancer Research

PubMed: MeSH publication types

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1080/10428194.2018.1563691

Otros archivos y enlaces

Citar esto

Al-Mansour, Z., Li, H., Cook, J. R., Constine, L. S., Couban, S., Stewart, D. A., Shea, T. C., Porcu, P., Winter, J. N., Kahl, B. S., Smith, S. M., Marcellus, D. C., Barton, K. P., Mills, G. M., LeBlanc, M., Rimsza, L. M., Forman, S. J., Leonard, J. P., Fisher, R. I., ... Stiff, P. J. (2019). Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leukemia and Lymphoma, 60(8), 1934-1941. https://doi.org/10.1080/10428194.2018.1563691

Al-Mansour, Z, Li, H, Cook, JR, Constine, LS, Couban, S, Stewart, DA, Shea, TC, Porcu, P, Winter, JN, Kahl, BS, Smith, SM, Marcellus, DC, Barton, KP, Mills, GM, LeBlanc, M, Rimsza, LM, Forman, SJ, Leonard, JP, Fisher, RI, Friedberg, JW & Stiff, PJ 2019, 'Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis', Leukemia and Lymphoma, vol. 60, n.º 8, pp. 1934-1941. https://doi.org/10.1080/10428194.2018.1563691

@article{1113bbee3fe74a899036ffd9da76a8b4,

title = "Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis",

abstract = "Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility (n = 1), choice (n = 2), or progression (n = 9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (p =.56), and 40% vs. 45% (p =.98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.",

author = "Zeina Al-Mansour and Hongli Li and Cook, {James R.} and Constine, {Louis S.} and Stephen Couban and Stewart, {Douglas A.} and Shea, {Thomas C.} and Pierluigi Porcu and Winter, {Jane N.} and Kahl, {Brad S.} and Smith, {Sonali M.} and Marcellus, {Deborah C.} and Barton, {Kevin P.} and Mills, {Glenn M.} and Michael LeBlanc and Rimsza, {Lisa M.} and Forman, {Stephen J.} and Leonard, {John P.} and Fisher, {Richard I.} and Friedberg, {Jonathan W.} and Stiff, {Patrick J.}",

note = "Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180888, CA180819, CA180820, CA180821, CA180863, CCSRI #021039; legacy grants CA46282, CA04919, CA11083, CA58658, CA46368, CA13612; and in part by Bristol-Myers Squibb. The content is solely the responsibility of the authors and does not necessarily represent the official views of either the National Institutes of Health or Bristol-Myers Squibb. Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = jul,

day = "3",

doi = "10.1080/10428194.2018.1563691",

language = "English",

volume = "60",

pages = "1934--1941",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma

T2 - a SWOG 9704 intergroup trial subgroup analysis

AU - Al-Mansour, Zeina

AU - Li, Hongli

AU - Cook, James R.

AU - Constine, Louis S.

AU - Couban, Stephen

AU - Stewart, Douglas A.

AU - Shea, Thomas C.

AU - Porcu, Pierluigi

AU - Winter, Jane N.

AU - Kahl, Brad S.

AU - Smith, Sonali M.

AU - Marcellus, Deborah C.

AU - Barton, Kevin P.

AU - Mills, Glenn M.

AU - LeBlanc, Michael

AU - Rimsza, Lisa M.

AU - Forman, Stephen J.

AU - Leonard, John P.

AU - Fisher, Richard I.

AU - Friedberg, Jonathan W.

AU - Stiff, Patrick J.

N1 - Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180888, CA180819, CA180820, CA180821, CA180863, CCSRI #021039; legacy grants CA46282, CA04919, CA11083, CA58658, CA46368, CA13612; and in part by Bristol-Myers Squibb. The content is solely the responsibility of the authors and does not necessarily represent the official views of either the National Institutes of Health or Bristol-Myers Squibb. Publisher Copyright: © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility (n = 1), choice (n = 2), or progression (n = 9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (p =.56), and 40% vs. 45% (p =.98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.

AB - Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility (n = 1), choice (n = 2), or progression (n = 9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (p =.56), and 40% vs. 45% (p =.98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.

UR - http://www.scopus.com/inward/record.url?scp=85059896704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059896704&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1563691

DO - 10.1080/10428194.2018.1563691

M3 - Article

C2 - 30628511

AN - SCOPUS:85059896704

SN - 1042-8194

VL - 60

SP - 1934

EP - 1941

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 8

ER -

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto